Venous Thromboembolism in Patients with Renal Transplantation

D. Poli¹, L. Migliaccio², E. Antonucci², L. Biancone³, G. Ghigliotti⁴, G. La Manna⁵, A. Ranghino⁶, P. Rigotti⁷, S. Tentori⁸, M. Zanazzi², G. Palareti²

¹Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, ²Fondazione Arianna Anticoagulazione, Bologna, Italy, ³Università di Torino, Torino, Italy, ⁴Università di Genova, Genova, Italy, ⁵Università di Bologna, Bologna, Italy, ⁶Ospedali Riuniti di Ancona, Ancona, Italy, ⁷Università di Padova, Padova, Italy, ⁸Ospedale San Raffaele, Milano, Italy

Abstract Number: PB2372

Meeting: ISTH 2020 Congress

Theme: Venous Thromboembolism and Cardioembolism » VTE Prophylaxis

Background: Scant data are available about the characteristics and optimal treatment of the episode of venous thromboembolism (VTE) occurring in renal transplant (RT) recipients.

Aims: Our study was undertaken to evaluate the characteristics of VTE in RT patients, the type of treatment used in clinical practice and the risk of recurrent VTE.

Methods: We performed a multicentric retrospective observational study among 7 Italian centers. Data were collected in a web based clinical report form with the use of REDCAP system.

Results: 112 patients who received renal transplantation (74 males 64%) and who developed a first episode of VTE after transplantation. Median age (range) at transplantation was 57 (22-76) years. Median time of VTE recurrence from RT was 6 (0.1-213) months; 783% of patients received RT from deceased donor; 10 patients (9.0%) ha kidney and pancreas transplantation. Characteristics of site and type of VTE and treatment of VTE are reported in table 1. During follow-up 84/112 patients stopped anticoagulant treatment. Among them 25 (30%) had recurrent VTE episodes.

Conclusions: We confirm the low rate of pulmonary embolism in RT patients with respect to general population. Instead, RT patients showed a high rate of recurrence accordingly with previous findings.

Patients	112
DVT	90(85.7%)
EP	4 (3.8%)
DVT/EP	11 (10.4%)
Unprovoked	78 (73.5%)
Secondary to transient risk factors	28 (26.5%)
LMWH/warfarin	55 (52.4%)
Warfarin	41 (39.0%
DOACs	9 (8.6%)
Median (range) duration of treatment, months	6 (1-144)

[Site and type of VTE, treatment of VTE]

To cite this abstract in AMA style:

Poli D, Migliaccio L, Antonucci E, Biancone L, Ghigliotti G, La Manna G, Ranghino A, Rigotti P, Tentori S, Zanazzi M, Palareti G. Venous Thromboembolism in Patients with Renal Transplantation [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-with-renal-transplantation/. Accessed May 16, 2022.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-with-renal-transplantation/